中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2013年
4期
95-97
,共3页
重组人红细胞生成素%肿瘤%贫血
重組人紅細胞生成素%腫瘤%貧血
중조인홍세포생성소%종류%빈혈
Recombinant human erythropoietin%Neoplasm%Anemia
目的 观察高剂量重组人红细胞生成素(RHEpo)冲击治疗恶性肿瘤贫血的临床疗效及不良反应.方法 将86例恶性肿瘤贫血患者随机分为对照组(RHEpo 1万U,每周3次,共6周)与高剂量组(RHEpo 4万U/次,第1、3天,RHEpo 2万U/次,第6、9、12、15、18、21、24天).治疗期间加强患者心理护理,合理用药,严密观察病情,及时处理并发症.所有患者共观察6周,每2周进行1次疗效评价,评价指标包括患者的血红蛋白值、有效率、输血率、停药者比率及药物的不良反应.结果 对照组4周后血红蛋白值明显升高,高剂量组治疗2周后血红蛋白值明显升高；高剂量组的4、6周血红蛋白值均高于对照组(P＜0.05)；高剂量组的2、4、6周有效率分别为40.5％、54.8％、71.4％,高于对照组的19％、28.6％、50.0％(P＜0.05)；两组输血率及不良反应率比较差异无统计学意义(P＞0.05).结论 高剂量RHEpo冲击治疗恶性肿瘤贫血的疗效优于常规剂量法,不良反应无明显增加,合理护理是RHEpo充分发挥疗效的关键.
目的 觀察高劑量重組人紅細胞生成素(RHEpo)遲擊治療噁性腫瘤貧血的臨床療效及不良反應.方法 將86例噁性腫瘤貧血患者隨機分為對照組(RHEpo 1萬U,每週3次,共6週)與高劑量組(RHEpo 4萬U/次,第1、3天,RHEpo 2萬U/次,第6、9、12、15、18、21、24天).治療期間加彊患者心理護理,閤理用藥,嚴密觀察病情,及時處理併髮癥.所有患者共觀察6週,每2週進行1次療效評價,評價指標包括患者的血紅蛋白值、有效率、輸血率、停藥者比率及藥物的不良反應.結果 對照組4週後血紅蛋白值明顯升高,高劑量組治療2週後血紅蛋白值明顯升高；高劑量組的4、6週血紅蛋白值均高于對照組(P＜0.05)；高劑量組的2、4、6週有效率分彆為40.5％、54.8％、71.4％,高于對照組的19％、28.6％、50.0％(P＜0.05)；兩組輸血率及不良反應率比較差異無統計學意義(P＞0.05).結論 高劑量RHEpo遲擊治療噁性腫瘤貧血的療效優于常規劑量法,不良反應無明顯增加,閤理護理是RHEpo充分髮揮療效的關鍵.
목적 관찰고제량중조인홍세포생성소(RHEpo)충격치료악성종류빈혈적림상료효급불량반응.방법 장86례악성종류빈혈환자수궤분위대조조(RHEpo 1만U,매주3차,공6주)여고제량조(RHEpo 4만U/차,제1、3천,RHEpo 2만U/차,제6、9、12、15、18、21、24천).치료기간가강환자심리호리,합리용약,엄밀관찰병정,급시처리병발증.소유환자공관찰6주,매2주진행1차료효평개,평개지표포괄환자적혈홍단백치、유효솔、수혈솔、정약자비솔급약물적불량반응.결과 대조조4주후혈홍단백치명현승고,고제량조치료2주후혈홍단백치명현승고；고제량조적4、6주혈홍단백치균고우대조조(P＜0.05)；고제량조적2、4、6주유효솔분별위40.5％、54.8％、71.4％,고우대조조적19％、28.6％、50.0％(P＜0.05)；량조수혈솔급불량반응솔비교차이무통계학의의(P＞0.05).결론 고제량RHEpo충격치료악성종류빈혈적료효우우상규제량법,불량반응무명현증가,합리호리시RHEpo충분발휘료효적관건.
Objective To study the clinical effect and side effect of high-dose recombinant human erythropoietin (RHEpo)on anemic patients with malignancies.Methods Eighty-six anemic patients with malignancies were randomly divided intomatched group(rhEPO 10 000 U were administered three times weekly for up to six weeks) or high-dose group (the specific use for the first 1,3 days for erythropoietin 40000U,and then in the first 6,9,12,15,18,21,24 days given erythropoietin 20000U every day).Strengthen psychological nursing,rational use of drugs,condition observation,management of complications during the course of treatment.The patients were observed for 6 weeks,and evaluated every 2 weeks.The evaluation indexes including hemoglobin value,efficient rate,blood transfusion rate,the ratings and adverse reaction.Results Hemoglobin level of high-dose group increased significantly after treatment of 2 weeks,while that of matched group increased significantly after treatment of 4 weeks.The main hemoglobin level in high-dose group was higher than those in matched group after treatment of 4 and 6 weeks(P ＜0.05).The effect rates of 2,4,6 weeks were 40.5％ 、54.8％ 、71.4％ respectively in high-dose group,higher than 19％ 、28.6％ 、50.0％ respectively in matched group (P ＜ 0.05).There were no significant differences in side effect and transfusion rate between the two groups (P ＞ 0.05).Conclusions The effect of high-dose RHEpo is better than RHEpo with common doses on anemic patients with malignancies.There is no difference in side effect between the two groups.Reasonable care plays an important role in the curative effect of RHEpo.
